ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Meloxicam

Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.

Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.

Drug pageMeloxicam: every studyMany companies study it; this page follows only the 66 they lead. All 88 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 4, 201466 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only220 open or runningphase 4since Jul 4, 2014May 2, 2002none ahead
Heron Therapeuticsits history only161 open or runningphase 4since Oct 1, 2021Jun 9, 2015none ahead
Baudax Bioits history only70 open or runningphase 4since Mar 15, 2022Aug 31, 2015none ahead
Alkermesits history only30 open or runningphase 3since Sep 15, 2011Jul 23, 2009none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jul 12, 2010Jul 12, 2010none ahead
Eurofarma Laboratoriosits history only20 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Grünenthalits history only20 open or runningphase 3since Sep 22, 2014Mar 18, 2013none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Feb 6, 2009Feb 6, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead

Also a collaborator on its studies: Eurotrials Brasil Consultores Cientificos Ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2008First studies: 2 phase 1 studies in HealthyFirst studyNCT00649675, NCT00649077

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
EtoricoxibruleOrganonphase 435
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 2 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00649675Healthy · United States1CompletedSep 200427
NCT00649077Healthy · United States1CompletedSep 200430

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “N1539”, 18 entries
  • “Meloxicam”, 12 entries
  • “Meloxicam tablet”, 3 entries
  • “Meloxicam 15 mg Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.